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Abstract
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Objective—Inconclusive findings about infection risks, importantly the use of
immunosuppressive medications, in patients who have undergone large-joint total joint
arthroplasty challenge efforts to provide evidenced-based perioperative total joint arthroplasty
recommendations to improve surgical outcomes. Thus, the aim of this study was to describe risk
factors for developing a postoperative infection in patients undergoing TJA of a large joint [total
hip arthroplasty, total knee arthroplasty, or total shoulder arthroplasty] by identifying clinical and
demographic factors, including the use of high risk medications (i.e., prednisone and
immunosuppressive medications) and diagnoses (i.e., rheumatoid arthritis [RA], osteoarthritis
[OA], gout, obesity, diabetes mellitus), that are linked to infection status, controlling for length of
follow-up.
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Methods—A retrospective, case-control study (N = 2,212) using de-identified patient health
claims information from a commercially-insured, U.S. dataset representing 15 million patients
annually (January 1, 2007 - December 31, 2009) was conducted. Descriptive statistics, t-test, chisquare test, Fisher's exact test, and multivariate logistic regression were used.
Results—Male gender (OR = 1.42; p < .001), diagnosis of RA (OR = 1.47; p = .031), diabetes
mellitus (OR = 1.38, p = .001), obesity (OR = 1.66, p < .001) or gout (OR = 1.95; p = .001), and a
prescription for prednisone (OR = 1.59; p < .001) predicted a post-operative infection following
total joint arthroplasty. Persons with post-operative joint infections were significantly more likely
to be prescribed allopurinol (p = .002) and colchicine (p = .006; no significant difference was
found for the use of specific disease modifying anti-rheumatic drugs and TNF-α inhibitors.
Conclusion—High-risk, post-operative joint infection groups were identified allowing for
precautionary clinical measures to be taken.

Author Manuscript

Keywords
Total joint arthroplasty; infections; risk factors; immunosuppressive medications; perioperative
management; case-control study

1. Introduction

Author Manuscript

Due to the high number of persons undergoing total large joint arthroplasty in the U.S., a
clear understanding of the risk of infection and related hospital readmissions and surgical
revisions is important [1-8]. Specifically, in the U.S., there were 719,000 total knee
arthroplasties -, 332,000 total hip arthroplasties, and 29,127 total shoulder arthroplasties
carried out in 2010 with annual costs estimated to be$18.7 billion.[1-3] Infection is reported
as a leading cause of hospital readmission following a total joint arthroplasty (post-operative
joint infection rates: 0.3% - 0.7%).[4-6] An estimated 14% of hospital readmissions
following total joint arthroplasty are a result of deep or superficial surgical site infection and
44% of joint revisions are a result of infections.[4-8]

Author Manuscript

In efforts to improve infection rates, prior research studies have identified high-risk groups
which have included: male gender (odds ratio [OR]: total knee arthroplasty - 1.89; total
shoulder arthroplasty - 2.59; total joint arthroplasty - 1.79); age older or younger than 56 65 years (OR: total knee arthroplasty - 1.42 - 2.59); diagnosis of diabetes mellitus (DM; OR:
total knee arthroplasty - 1.28; total hip arthroplasty - 1.77); scoring at or higher than 2 on the
American Society of Anesthesiologist Scale (OR: total knee arthroplasty - 1.42 - 1.65; total
hip arthroplasty - 1.95 - 2.74; TSA - 1.41); history of cancer (OR: total knee arthroplasty 11.73); higher Charlson Comorbidity Score (OR: total joint arthroplasty - 2.29 [Score ≥ 2];
total knee arthroplasty - 2 [Score > 3]); current smoker (OR: total knee arthroplasty or total
hip arthroplasty - 1.41); and Body Mass Index ≥ 35 (OR: total knee arthroplasty - 1.47; total
hip arthroplasty -3.02; total shoulder arthroplasty - 2.48). Yet, there are inconsistencies in the
variables investigated and study findings.[7-18] Similarly, many of these risk factors are
largely unmodifiable in the perioperative period.
Because of the potential for modification, an understanding of risks of immunosuppressive
medications on rates of infection and readmission following total joint arthroplasty is
Semin Arthritis Rheum. Author manuscript; available in PMC 2018 February 01.
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needed. Prior research on this topic is largely based on studies of rheumatoid arthritis (RA)
patients.[8,19,20] Research suggests use of traditional disease modifying antirheumatic
drugs (DMARDs), a nonbiologic class of immunosuppressive medications used to treat RA,
prior to surgery does not increase infection risk.[20] In contrast, steroid use has been found
to increase risks of infection and hospital readmission.[19,21] There are conflicting findings
on TNF inhibitor use (biologic medications used to treat RA) and infection risk.[20-26]

Author Manuscript

Studies investigating the role of immunosuppressive medications in RA patients have not
clearly described the role of treatment versus disease-related (inflammatory arthritis versus
noninflammatory arthritis) effects on postoperative infection risks. [9,10,27-29] Two
retrospective U.S. studies found no difference in infection rates between those diagnosed
with RA versus osteoarthritis (OA) in persons who had undergone a total hip arthroplasty or
total knee arthroplasty.[9,10] Yet, a number of studies have reported increased risks of
infection in patients with RA ranging from two to four times that of patients with OA.
[5,15,19,27] Singh and colleagues (N = 34,311) recently reported that persons with RA are
1.29 times more likely to be readmitted to the hospital for post-surgical complications
(infection leading cause), and that these rates were increasing yearly (0.85, 1.37, and 1.63 in
2009, 2010, and 2011, respectively).[4] Interpretation of the literature is complicated by the
inconsistent antibiotic protocols, definitions of infection, and sampling.[28]

Author Manuscript

Evidence-based perioperative management for total joint arthroplasty is limited by the lack
of conclusive research findings about risk factors, the role of immunosuppressive
medications, and the role of type of arthritis (OA versus RA) in the development of an
infection following total joint arthroplasty.[9,10,27, 29] The aim of this study was to
describe risk factors for developing post-operative infections in patients undergoing total
joint arthroplasty of a large joint (total hip arthroplasty, total knee arthroplasty, or total
shoulder arthroplasty). To achieve this aim, initially we identified clinical and demographic
factors, including the use of high risk medications (i.e., prednisone and immunosuppressive
medications) and diagnoses (i.e., gout, obesity, DM, RA, OA), that are linked to infection
status, controlling for length of follow-up by comparing cases and control and using logistic
regression modeling. During this iterative process, we further explored the potential for
clinical and demographic factors that moderate the relationship between RA/OA diagnosis
and infections post-operatively.

2. Materials and Methods
2.1. Procedure and Sample

Author Manuscript

De-identified patient health claims information was extracted retrospectively from a dataset
representing a commercially-insured, U.S. population of 15 million patients annually from
January 1, 2007 to December 31, 2009. This dataset includes 1,284,681 prescribers and
3,631 health care provider designations from all geographic regions in the U.S. Patient-level
data was extracted including: administrative demographic data (e.g., gender, age), pharmacy
claims data (e.g., national drug code), and physician and facility claims (e.g., procedure
codes, diagnosis codes). Medical Institutional Review Board approval was obtained for the
use of this dataset.

Semin Arthritis Rheum. Author manuscript; available in PMC 2018 February 01.
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First, all patients with the diagnosis of OA (ICD-9: 715.0 - 715.9) and RA (ICD-9: 714.0,
714.2, 714.4) who had a total joint arthroplasty (CPT codes: total knee arthroplasty - 27447;
total hip arthroplasty - 27130; total shoulder arthroplasty - 23472) were extracted from the
database which resulted in 55,861 unique persons. Patients who developed a post-operative
joint infection following total joint arthroplasty surgery (ICD-9: 996.66 - Infection and
inflammatory reaction due to internal joint prosthesis) were identified as cases (Figure 1). Of
the 55,861 patients followed during this 2-year period, 1,127 developed a post-operative
infection following total joint arthroplasty surgery and therefore were defined as cases in this
study. Only one operative event was included for a given patient. If a patient had more than
one total joint arthroplasty, only the first surgery was retained in this analysis. The only
exception to this was if a patient had a subsequent total joint arthroplasty surgery that
resulted in infection; in this case, only the information from the first surgery associated with
an infection was retained. Controls were randomly selected to frequency match cases based
on age (within 10-year increments) with a 1:1 sampling ratio; therefore only persons with
complete data on matching criteria were eligible. Ten cases had missing data on year of birth
and were excluded from the study; 11 cases were omitted because they did not have
confirmation of OA or RA diagnosis, since the corresponding ICD-9 code was listed only
once in their record; therefore the final sample consisted of 2,212 patients: 1,106 cases and
1,106 controls.
2.2. Measures

Author Manuscript

2.2.1. Demographic and clinical characteristics—Demographic information
extracted from the database included age, gender, and race (White, Other race). We also
retained information on surgery location (i.e., hip, knee, or shoulder) and time between date
of surgery and end of study (i.e., length of follow-up in days). Based on prior research,
ICD-9 codes were used to extract clinical information for comorbid conditions including:
human immunodeficiency virus infection and acquired immune deficiency syndrome [HIV/
AIDS], immunodeficiency conditions, cancer, systemic lupus erythematosus [SLE], diabetes
mellitus [DM], obesity/morbid obesity, and gout.[30-33]
We also collected information on concomitant prescription drug information. Prednisone
was abstracted as dose (mg) and supply (days) for each individual; only prescriptions within
one month before surgery or following, which we defined as the perioperative period, were
included. Because the majority of the sample (77%) was not prescribed prednisone, a binary
variable indicating yes or no to prednisone use was created to include in the analysis.
Medications were classified as immunosuppressive based on an updated Center for Disease
Control list of Immunosuppressive Medications.[34]

Author Manuscript

2.2.2. Infection status—Medical outcome data were used to identify patients receiving
treatment for post-operative joint infections (ICD-9: 996.66 - Infection and inflammatory
reaction due to internal joint prosthesis). For each patient, a binary variable was created to
indicate whether or not the patient received care for an infection attributed to the total joint
arthroplasty. This variable was used to distinguish cases and controls, and was the outcome
in this study.

Semin Arthritis Rheum. Author manuscript; available in PMC 2018 February 01.
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Data were summarized using descriptive statistics. Initially, comparisons of study variables
between cases and controls were accomplished using the two-sample t-test, Mann-Whitney
U test, chi-square test of association or Fisher's exact test. Then, a series of logistic
regression models were used. First, a main effects model was fit to identify demographic and
clinical characteristics predictive of infection status. In addition to typical demographic/
clinical factors, we also included length of follow-up in each model as an adjustment for
longer median follow-up among cases relative to controls. Through an iterative process, a
test of moderation between diagnosis of RA or OA and post-operative infection status was
conducted using a second logistic regression model which included the interactions between
diagnosis (RA vs. OA) and the potential moderator variables (i.e., each demographic and
clinical factor). Due to the concern about estimate stability, interaction terms involving
conditions of very low prevalence (i.e., cancer, immunodeficiency, SLE, each affecting less
than 5% of sample) were not included. In a subsequent analysis, all nonsignificant
interactions were removed from the model. For the significant interaction effects retained,
the association between RA or OA diagnosis and infection risk was evaluated at each level
of the moderator variable. The Hosmer-Lemeshow goodness-of-fit test evaluated overall
model fit, and variance inflation factors were used to check for multicollinearity. For these
data analyses, SAS version 9.3 was used with an alpha level of .05.

3. Results
3.2. Description of Sample

Author Manuscript

The mean age of the case-control sample was 59.8 years (SD = 10.2 years). The majority of
the sample was female (51.1%) and White (83.1%; Table 1). The most common total joint
arthroplasty was total knee arthroplasty (61.5%), followed by total hip arthroplasty (35.7%)
and total shoulder arthroplasty (2.8%); the median length of follow up among all patients
was 555 days. The prevalence of comorbid conditions included obesity (30.5%), DM
(29.4%), gout (6.4%), SLE (2.5%), cancer (2.5%), an immunodeficiency condition (1.0%),
and/or HIV/AIDS (0.4%). Nearly one-quarter of patients (22.7%) were prescribed
prednisone in the two-month perioperative period; 13.5% took at least one
immunosuppressive medication during the perioperative period. In the total sample, among
those on prednisone, the median average daily dose was 0.16mg (0.07mg – 0.47mg).
3.3. Identification of Clinical and Demographic Risk Factors

Author Manuscript

When comparing cases to controls, those with an infection were more likely to be male
(52.1% vs. 45.7%; p = .002; Table 1). Persons who experienced an infection also had a
longer median length of follow up (577 days) compared with those who did not (526 days; p
< .001). In addition, persons in the case group (i.e., those with an infection) were more likely
to have been diagnosed with lupus (3.4% vs. 1.6%; p = .007), DM (34.1% vs. 24.8%; p < .
001), obesity (35.8% vs. 25.2%; p < .001), and gout (8.9% vs. 3.9%; p < .001). Those with
infections were more likely to have an RA diagnosis compared to those in the control group
(9.2% vs. 6.1%, p = .005). Consistent with the age-matching of controls with cases, there
was no difference on age (t = 0.4; p = .7). In addition, cases and controls did not differ on
race, surgery location, or prevalence of cancer, immunodeficiency conditions, or HIV/AIDS.
Semin Arthritis Rheum. Author manuscript; available in PMC 2018 February 01.
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In the bivariate analysis of medication use relative to post-operative infection status, a higher
proportion of cases were prescribed prednisone (27.7% vs. 17.7%; p < .001) or an
immunosuppressive medication (16.6% vs. 10.4%; p < .001) at least once during the
perioperative period, compared with controls. For each immunosuppressive drug used by at
least five patients in the sample, individual drugs and drug categories were compared
between cases and controls (Figures 2 and 3). The only significant differences between cases
and controls for prevalence of specific immunosuppressive drugs and drug categories
included allopurinol (χ2 = 9.2; p = .002) and colchicine (χ2 = 7.5; p = .006. Figures 2 and 3
also display, at the top of each bar, the percent of patients using the particular medication (or
medication class) that were also diagnosed with RA. Given that the sample comprised 8%
RA patients, medications with RA use prevalence in excess of this demonstrates that more
RA patients were taking these drugs that would have been expected if both diagnoses were
equally likely to do so. Nearly all of those using adalimumab, leflunomide, or methotrexate
were RA patients, while nearly all of those using allopurinol, fluorouracil, or megestrol were
OA patients (Figure 2). More than two-thirds of those taking a TNFα inhibitor or DMARD
were diagnosed with RA, regardless of whether they were in the infection (case) group or
not (Figure 3).
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The main effects multiple logistic regression model was significant overall (χ2 = 129.8; p < .
001). Length of follow-up was associated with infection risk. For each additional 100 days
of follow-up, a patient was 4% more likely to have an infection in a prosthetic joint (OR =
1.04; p = .004; Table 2). Males, compared to females, were 42% more likely to develop an
infection post-operatively (OR = 1.42; p < .001). Patients with a DM diagnosis were 38%
more likely to develop an infection, relative to those without this diagnosis (OR = 1.38; p = .
001). Other comorbid conditions associated with increased infection risk included obesity
(OR = 1.66, p <.001) and gout (OR = 1.95; p = .001). Controlling for demographic and
clinical characteristics and length of follow-up, RA patients were 47% more likely to
develop a post-operative infection, compared to patients with OA (OR = 1.47; p = .031).
Patients prescribed prednisone within one month before or following total joint arthroplasty
surgery were 59% more likely to develop an infection, compared to those not prescribed
prednisone (OR = 1.59; p < .001). Race, total joint arthroplasty location, cancer, SLE,
presence of an immunodeficiency condition, HIV/AIDS, and use of an immunosuppressive
medication during the perioperative period were not predictive of post-operative infection in
the main effects model. The Hosmer-Lemeshow goodness-of-fit test was not significant (χ2
= 5.2; p = .74), suggesting the model fit the data well. All variance inflation factors were less
than 1.4, indicating that multicollinearity was not distorting the parameter estimates.
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In an effort to investigate treatment versus disease-related effects, the relationship between
RA/OA diagnosis and infection identified in our primary analysis was explored using a
second logistic regression model. This moderation model, which contained demographic and
clinical main effects, days of follow-up, the indicator for RA/OA, and the interaction
between immunosuppressive medication use and RA/OA diagnosis was significant (χ2 =
8.3; p = .004). Among those taking immunosuppressive medication(s) (n = 299), there was
no difference in the odds of infection between RA (n = 71) and OA patients (n = 229; OR =
0.73, p = .30); however, among those not taking this type of medication (n = 1,913), RA
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patients (n = 99) were 130% more likely to develop an infection compared with OA patients
(n = 1,814; OR = 2.30, 95% Confidence Interval: 1.37 – 3.30; p = .001).

4. Discussion

Author Manuscript

The lack of conclusive research findings about risk factors, importantly the role of
immunosuppressive medications, in the development of an infection following total joint
arthroplasty, has limited evidenced-based perioperative management. Similarly there is a
lack of clarity on the role of disease- versus treatment-related effects on infection risk
following total joint arthroplasty. In efforts to address these clinical problems, we identified
risk factors for developing infections following a total joint arthroplasty of a large joint.
Using an iterative process we also described the moderating relationship between the use
immunosuppressive medications and the diagnosis of RA/OA in the development of a postoperative infection.
There is evidence that supports and conflicts with our finding that there is an increased risk
of infection following total joint arthroplasty in patients with RA versus those with OA.
Large U.S. and European studies have reported an increased risk of hospital readmissions
and infections in patients with RA versus those with OA. [4,27,30] In contrast, Namba and
colleagues did not find an increased risk of infection between persons with RA and OA
following total hip arthroplasty or total knee arthroplasty in a retrospective analysis of data
from 2001-2009.[9,10] Considering that the majority and the most recent and large studies
found an increased risk of postoperative infection in patients with RA, we feel our findings
are strongly supported; thus, this risk factor should be considered during clinical
management.

Author Manuscript
Author Manuscript

Although the increased infection risk of RA versus OA has been further established, the
question of disease- versus treatment-related effects remained.[29] Because of the study
design using a large administrative dataset, we could not directly assess RA disease activity.
However, importantly in our study, immunosuppressive medication use did not predict
infection in our main effects model and the use of immunosuppressive medications only
moderated the relationship between RA/OA diagnosis and infection in the postoperative
period: while the main effects model demonstrated that RA patients were at an increased risk
for infection compared with OA patients, the test of moderation indicated this phenomenon
was only present among those not taking immunosuppressive medications perioperatively.
These findings support prior studies suggesting there is not an increased infection risk when
using immunosuppressive medications (DMARDs) prior to surgery.[19, 20] Our study
conflicts with prior research reporting that patients taking biologic DMARDs within 2 to 4
weeks of surgery were 5.7 times more likely to develop an infection.[20] Of interest, persons
in the this same study who had increased RA disease duration were also more likely to
develop an infection.[20] We found there was not a significant different between cases and
control on the use of TNF-α inhibitors as a class, and this was bolstered with the casecontrol comparison of percentage using adalimumab specifically. We confirmed prior
evidence to suggest that steroid use increases the risk of infection and hospital readmission.
[8,19]
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Our findings suggesting that, controlling for obesity and DM, gout and medications used to
treat gout increase infection risk following total joint arthroplasty. These findings are
supported by one study conducted by Inacio and colleagues (OR - 1.3).[27] Interestingly, a
recent publication reported 7 cases of crystal induced arthritis followed total joint
arthroplasty suggesting our understanding of the relationship between gout, total joint
arthroplasty and infection is evolving and further exploration is needed [35]. Similarly,
because the increased risk of infection has been described in two diseases with inflammatory
etiologies (RA and gout), the role of inflammation in the diagnosis of postoperative infection
also requires further exploration.
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Prior research supports study findings that male gender, DM, and obesity predict
postoperative infection following total joint arthroplasty.[9,10] Interestingly, weight loss has
also been identified as a risk factor for developing a post-operative infection (OR: 2.3)
complicating clinical recommendations to obese persons.[27]
The effect of cancer diagnosis on infection risk following total joint arthroplasty is
conflicting in prior research. [8,31] Findings from this study suggest that persons with a
history of cancer are not at increased infection risk. Although we did report the use of
immunosuppressive medication use, which provides insight into cancer as an infection risk
factor, further prospective research on the effects of cancer stage and specifics of cancer
treatment should be conducted. Neither our findings nor prior research suggest that those
diagnosed with HIV/AIDS are at increased risk of infection following total joint
arthroplasty.[31] Despite our study findings, there are relatively few studies describing the
risk of HIV/AIDS and cancer and postoperative infection, which limits evidenced-based
practice.
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A study strength is the large number of patients included relative to prior research in this
area. Because this was a retrospective review of a commercial insurance database, the data
available was limited by those medications and treatments that were charged by health care
providers and paid for using insurance coverage. Although this was a large dataset, it
represents those commercially insured and study findings may not be generalizable to other
populations, including those without private insurance. The racial/ethnic composition of the
sample is notrepresentative of the U.S. population, though the higher prevalence of White
patients in this sample relative to the general population is consistent with previous studies
of racial variations in total joint arthroplasty [36]. There is also the potential for inaccuracies
in ICD-9 and CPT codes available for extraction from the dataset, though limited the
analysis to those with confirmed RA/OA by requiring at least two ICD-9 codes for the
respective disease in each patient retained in the analysis to prevent a diagnosis error. The
modest number of persons with HIV/AIDS, cancer, SLE, and immunodeficiency conditions
limit the strength of this analysis as least as it pertains to definitive understanding of the link
between these conditions and infection risk. The test of moderation between RA/OA status
and infection should be confirmed in a sample that includes more RA patients, and more
patients who are taking immunosuppressive medications. In particular, given the relatively
small percentage of patients with RA compared with OA in addition to the low prevalence of
use for individual immunomodulating and immunosuppressive medications, it was not
possible to investigate the relationship between infection risk and diagnosis of OA/RA for
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each of these medications. This last limitation is mitigated by the observation that the risk of
infection among RA patients relative to those with OA was elevated only among those not
taking immunosuppressive medications, but there was no risk differential among those who
were.

5. Conclusion
In conclusion, this study uses a robust sample to validate previously-identified risk factors
(i.e., male gender, obesity) and further clarify risk factors with conflicting or very little prior
research (i.e., gout, prednisone, immunosuppressive medication use). These findings
contribute to our understanding of treatment- versus disease-related infection risks following
total joint arthroplasty.
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RA

rheumatoid arthritis

OA

osteoarthritis

U.S

United States

OR

odds ratio

DM

diabetes mellitus

DMARDs

disease modifying anti-rheumatic drugs

TNFα

tumor necrosis factor alpha

CPT

current procedural terminology

ICD-9

International Statistical Classification of Disease

HIV/AIDs

human immunodeficiency virus infection and acquired immune deficiency
syndrome

SLE

systemic lupus erythematosus
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Derivation of Sample.
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Figure 2.

Comparisons of medication usage rates between cases and controls.
Note: Above each bar is listed the percent of patients taking that drug who have RA, whether
in the case or control group; this should be contrasted to 8%, the percent of patients with RA
in the full sample of cases and controls. For example, all patients taking Adalimumab who
did not get infections had RA, and 80% of those in the case group who were taking this drug
had RA.
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Figure 3.

Author Manuscript

Comparison of use of TNFα inhibitors and traditional DMARDs between cases and
controls.
*TNFα inhibitors including Adalimumab, Certolizumab, Etanercept, Infliximab, and
Golimumab
±Traditional DMARDS including Azathioprine, Hydroxychloroquine, Leflunomide, and
Methotrexate
Note: Above each bar is listed the percent of patients taking that class of drug who have RA,
whether in the case or control group; this should be contrasted to 8%, the percent of patients
with RA in the full sample of cases and controls. For example, 93% of patients taking a
TNFα inhibitor who did not get infections had RA, and 69% of those in the case group who
were taking this class of drug had RA.
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Table 1

Descriptive summary of study variables and comparisons by infection status

Author Manuscript

Total sample (N = 2,212)

Case (n = 1,106)

Control (n = 1,106)

Gender

p
.002

Male

1,081 (48.9%)

576 (52.1%)

505 (45.7%)

Female

1,131 (51.1%)

530 (47.9%)

601 (54.3%)

White

1,838 (83.1%)

913 (82.5%)

925 (83.6%)

Other

374 (16.9%)

193 (17.5%)

181 (16.4%)

Knee

1,361 (61.5%)

692 (62.6%)

669 (60.5%)

Hip

789 (35.7%)

385 (34.8%)

404 (36.5%)

Shoulder

62 (2.8%)

29 (2.6%)

33 (3.0%)

555 (301 – 814.5)

577 (335 - 832)

525.5 (260 -786)

Yes

55 (2.5%)

33 (3.0%)

22 (2.0%)

No

2,157 (97.5%)

1,073 (97.0%)

1,084 (98.0%)

Race

.50

Surgery location

.58

Author Manuscript

Follow-up (days)
Cancer

<.001
.13

Lupus (SLE)

.007

Yes

56 (2.5%)

38 (3.4%)

18 (1.6%)

No

2,156 (97.5%)

1,068 (96.6%)

1,088 (98.4%)

Immunodeficiency condition

.087

Author Manuscript

Yes

22 (1.0%)

15 (1.4%)

7 (0.6%)

No

2,190 (99.0%)

1,091 (98.6%)

1,099 (99.4%)

Yes

9 (0.4%)

5 (0.5%)

4 (0.4%)

No

2,203 (99.6%)

1,101 (99.5%)

1,102 (99.6%)

Yes

651 (29.4%)

377 (34.1%)

274 (24.8%)

No

1,561 (70.6%)

729 (65.9%)

832 (75.2%)

HIV/AIDS

.74

Diabetes

<.001

Obesity

<.001

Yes

675 (30.5%)

396 (35.8%)

279 (25.2%)

No

1,537 (69.5%)

710 (64.2%)

827 (74.8%)

Author Manuscript

Gout

<.001

Yes

142 (6.4%)

99 (8.9%)

43 (3.9%)

No

2,070 (93.6%)

1,007 (91.1%)

1,063 (96.1%)

Perioperative prednisone use
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Total sample (N = 2,212)

Case (n = 1,106)

Control (n = 1,106)

Yes

502 (22.7%)

306 (27.7%)

196 (17.7%)

No

1,710 (77.3%)

800 (72.3%)

910 (82.3%)

Perioperative immunosuppressive medication use

p

<.001

Yes

299 (13.5%)

184 (16.6%)

115 (10.4%)

No

1,913 (86.5%)

922 (83.4%)

991 (89.6%)

Rheumatoid arthritis

169 (7.6%)

102 (9.2%)

67 (6.1%)

Osteoarthritis

2,043 (92.4%)

1,004 (90.8%)

1,039 (93.9%)

Diagnosis

.005

Note: all statistics are reported as n (%), except days of follow-up; this is reported as median (interquartile range)
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Table 2

Author Manuscript

Multiple logistic regression modeling the likelihood of developing a post-operative
infection following total joint replacement surgery (N = 2,212)
Estimated Odds Ratio (OR)

95% Confidence Interval for OR

p

1.42

1.19 – 1.70

<.001

0.93

0.74 – 1.17

.53

Hip vs. knee

1.01

0.84 – 1.21

.93

Shoulder vs. knee

0.78

0.46 – 1.33

.36

Follow-up (days) a

1.04

1.01 – 1.07

.004

1.34

0.76 – 2.36

.31

1.65

0.90 – 3.04

.11

1.78

0.69 – 4.57

.23

1.24

0.32 – 4.82

.76

1.38

1.14 – 1.68

.001

1.66

1.37 – 2.02

<.001

1.95

1.30 – 1.97

.001

1.59

1.28 – 1.97

<.001

1.12

0.84 – 1.50

.44

1.47

1.04 – 2.08

.031

Gender
Male vs. female
Race
White vs. other
Replacement surgery location

Author Manuscript

Cancer
Yes vs. no
Lupus (SLE)
Yes vs. no
Immunodeficiency condition
Yes vs. no
HIV/AIDS
Yes vs. no

Author Manuscript

Diabetes
Yes vs. no
Obesity
Yes vs. no
Gout
Yes vs. no
Perioperative prednisone use
Yes vs. no
Perioperative immunosuppressive medication use
Yes vs. no

Author Manuscript

Diagnosis
RA vs. OA

a

Estimates correspond to a 100 day increase days of follow-up
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